Unfavorable Survival Rates in Iranian Patients with Gastric Cancers: A Single Center Experience from Tehran
We examined the effect of potential interfering factors that play major roles in the outcome of our patients with stomach cancer. 100 consecutive patients diagnosed with gastric cancers were prospectively observed, treated and followed from November 2009 to January. Absence of Helicobacter pylori infection (P=0.027), absence of vascularisation (P<0.001), and undetermined histopathological type of adenocarcinoma (P=0.003) were factors significantly associated with higher grade of gastric lesions. Life tables were used to define survival of gastric cancers. Survival rates of these patients at 1st week, 1st month, 2nd month, 3rd month, and 6th month were 97%, 96%, 91%, 90%, and 82%, respectively. The only determinant of 6 months of survival was age over 68 (P=0.039). Our study confirms our previous knowledge that gastric cancers have unfavorable outcome in Iran.
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
Cancer. World Health Organization (Accessed in Jan 2014, 28, at http://www.who.int/mediacentre/factsheets/ fs297/en/).
Are the number of cancer cases increasing or decreasing in the world? World Health Organizatin. (Accessed in Jan2014, 24 at http://www.who.int/features/qa/15/en/index. html).
Stamatakos M, Kontzoglou K, Sargedi C, et al. Gastrointestinal carcinoid tumors:diagnosis and treatment. Chirurgia (Bucur) 2010;105(6):759-66.
Malekzadeh R, Sotoudeh M, Derakhshan MH, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol 2004;57(1):37-42.
Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric=cancer in Iran:epidemiology and risk factors. Arch Iran Med 2009;12(6):576-83.
Mousavi SM, Gouya MM, Ramazani R, et al. Cancer incidence and mortality in Iran. Ann Oncol2009;20(3):556-63.
The International Agency for Research on Cance, Hamilton SR, Aaltonen LA, editors. Pathology and genetics of tumors of the digestive system. Lyon, France: IARC Press; 2000: p. 31-6 .
Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20(10):1161-81.
Sadighi S, Raafat J, Mohagheghi M, et al. Gastric carcinoma: 5 year experience of a single institute. Asian Pac J Cancer Prev 2005;6(2):195-6.
Moghimi-Dehkordi B, Safaee A, Zali MR. Survival rates and prognosis of gastric cancer using an actuarial lifetable method. Asian Pac J Cancer Prev 2008;9(2):317-321
Khedmat H, Panahian M, Mashahdian M, et al. Prognostic factors and survival in stomach cancer - analysis of 15 years of data from a referral hospital in iran and evaluation of international variation. Onkologie 2011;34(4):178-82.
Somi MH, Farhang S, Mirinezhad SK, et al. Cancer in East Azerbaijan, Iran:results of a population-based cancer registry. Asian Pac J Cancer Prev 2008;9(2):327-30.
Semnani S, Sadjadi A, Fahimi S, et al. Declining incidence of esophageal cancer in the Turkmen Plain, eastern part of the Caspian Littoral of Iran:a retrospective cancer surveillance. Cancer Detect Prev 2006;30(1):14-9.
Sadiadi A, Zahedi MJ, Darvish Moghadam S, et al. The first population-based cancer survey in Kerman province of Iran. Iranian J Publ Health 2007;36(4):26-34.
Babaei M, Mousavi S, Malek M, et al. Cancer occurrence in Semnan Province, Iran:results of a population-based cancer registry. Asian Pac J Cancer Prev 2005;6(2):159-64.
Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, et al. Cancer incidence in Tehran metropolis:the first report from the Tehran Population-Based Cancer Registry, 1998-2001. Arch Iran Med 2009;12(1):15-23.
Abdi-Rad A, Ghaderi-sohi S, Nadimi-Barfroosh H, et al. Trend in incidence of gastric adenocarcinoma by tumor location from 1969-2004:a study in one referral center in Iran. Diagn Pathol 2006;1(1):5.
Wang LD, Guo RF, Fan ZM, et al. Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population. Dis Esophagus 2005;18(3):177-84.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.